Search
for
Sort by
Research 931–960 of 1000+
- Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis
- Novel inhibitors of 5α-reductase
- Pediatric Endocrine-Disrupting Chemical Exposure Produces Irreversible Organizational Injury: Biomarker Evidence Necessitating a Precautionary Public Health Framework
- Leydig Cell Hyperplasia and Adenomas in Mice Treated with Finasteride, a 5α-Reductase Inhibitor: A Possible Mechanism
- Treatment of Hair Loss
- Treatment of Hirsutism With Spironolactone
- Obesity and polycystic ovary syndrome
- MENSTRUAL DISORDERS IN ADOLESCENTS
- Anti-androgenic activities of Ganoderma lucidum
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
- Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial
- Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
- The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals
- Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
- Hirsutism
- Endocrine disorders and hormonal therapy for adolescent acne
- Diagnosis and treatments of hirsutism: where are we?
- Treatment guidelines in adult women
- Post-oncologic skin health: cutaneous recovery and rehabilitation after cancer treatments
- Polycystic Ovary Syndrome: Current Insights Into Etiology, Symptoms, And Treatment Options
- Recommendations on trichological treatments during COVID-19 pandemic
- Polycystic Ovarian Syndrome: The Androgenized Adolescent
- Androgenetic alopecia; drug safety and therapeutic strategies
- Hyperandrogenism in Adolescent Girls
- Treatment of female sexual dysfunction in postmenopausal women—What is the evidence?
- Testosterone therapy for transgender men
- Control of hair follicle cell fate by underlying mesenchyme through a CSL–Wnt5a–FoxN1 regulatory axis
- Androgens and Antiandrogens
- Rituximab for Bone Lymphoma
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database